Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD, 21224. United States.
Department of Neurosurgery, Krishna Institute of Medical Sciences (KIMS), Hyderabad- 500003, Telangana. India.
Curr Pharm Des. 2017;23(28):4170-4179. doi: 10.2174/1381612823666170208123553.
Adipokines are bioactive proteins that mediate proliferation, metabolism, inflammation, and angiogenesis. Adiponectin is an important adipokine that exerts multiple key functions via its anti-metabolic syndrome and anti-inflammatory properties. A number of adiponectin receptors, AdipoR1, AdipoR2 and T-cadherin, have been identified. Recent studies have suggested the involvement of adiponectin and receptors in several cancers, including prostate, breast, endometrial, brain, and colon cancer. Altered levels of adiponectin expression, or its interacting receptors, in cancers can lead to dysregulation of signaling pathways. Our current review describes the molecular mechanisms underlying the anti-tumorigenesis activity of adiponectin and the role of its receptors in prostate carcinogenesis, and provides perspectives of adiponectin-mediated signaling as a potential target for therapy.
脂联素是一种生物活性蛋白,可介导增殖、代谢、炎症和血管生成。脂联素是一种重要的脂肪因子,通过其抗代谢综合征和抗炎特性发挥多种关键功能。已经鉴定出许多脂联素受体,包括 AdipoR1、AdipoR2 和 T-钙黏蛋白。最近的研究表明,脂联素及其受体参与了多种癌症,包括前列腺癌、乳腺癌、子宫内膜癌、脑癌和结肠癌。癌症中脂联素表达或其相互作用受体的改变会导致信号通路失调。我们目前的综述描述了脂联素的抗肿瘤活性的分子机制及其受体在前列腺癌发生中的作用,并提供了脂联素介导的信号作为潜在治疗靶点的观点。